Opens in a new tab
Wednesday, 18 November 2026
EVIDENCE. INTERPRETED.
Advertisement · Remove ads
728 × 90
Clinical Trials

Altimmune Reports Strong Fibrosis Improvements With Pemvidutide in MASH

Altimmune presented new data from the Phase 2b IMPACT trial at the EASL Congress 2026, highlighting pemvidutide’s ability to improve overlapping non-invasive markers of MASH activity and fibrosis…

Written byFariha SameenReviewed byPharmacally Editorial Team27 May 2026 · 2 min read
Fact-Checked
Hand Care. Closeup of female hand in doctors coat ponting or holding Liver, Heart, Human anatomy. Medicine, healthcare and advertisement concept

Altimmune’s Phase 2b IMPACT trial shows pemvidutide improves MASH biomarkers and fibrosis, reinforcing antifibrotic potential after 24 weeks.

Altimmune unveiled new analyses from its Phase 2b IMPACT trial (NCT05989711) at the EASL Congress 2026, showing that pemvidutide improved multiple non-invasive markers of metabolic dysfunction-associated steatohepatitis (MASH) activity and fibrosis after 24 weeks of treatment. The findings reinforce the investigational therapy’s potential antifibrotic activity and provide additional evidence of consistent treatment effects across liver fat, inflammation, and fibrosis markers.

Pemvidutide Mechanism

Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for MASH, alcohol use disorder, and alcohol-associated liver disease. Glucagon receptor activation reduces liver fat, inflammation, and fibrosis, while GLP-1 activity supports appetite suppression and weight loss.

Biomarker Improvements

The new analyses assessed overlapping improvements in liver fat content (LFC), alanine aminotransferase (ALT), liver stiffness measurement (LSM), and enhanced liver fibrosis (ELF) scores. The analyses showed consistent improvements across both inflammatory and fibrosis-related markers.

At the 1.2 mg dose, 37.8% of patients achieved both a greater than 0.5 reduction in ELF score and more than 30% reduction in LSM versus 8.3% with placebo (p=0.0002). At the 1.8 mg dose, 22.7% achieved the same endpoint compared with placebo (p=0.02).

Digital Pathology Findings

AI-based digital pathology using HistoIndex qFibrosis technology confirmed consistent antifibrotic activity. Continuous fibrosis values declined significantly with pemvidutide, while at least one-stage qFibrosis regression occurred in 68.6% of patients receiving 1.2 mg and 54.5% receiving 1.8 mg, compared with 29.6% on placebo.

Expert Commentary

Naim Alkhouri, Chief Medical Officer at Summit Clinical Research, said the consistency across non-invasive markers and histologic assessments supports pemvidutide’s broad effect on MASH disease biology and fibrosis progression.

Christophe Arbet-Engels, Chief Medical Officer at Altimmune, said the combined biomarker and imaging findings strengthen confidence in the durability and robustness of the treatment response.

Study Design

The randomized, double-blind IMPACT Phase 2b trial enrolled 212 patients with biopsy-confirmed MASH and F2–F3 fibrosis, with and without diabetes. Participants received weekly subcutaneous pemvidutide at 1.2 mg, 1.8 mg, or placebo for 48 weeks. Primary endpoints included MASH resolution without fibrosis worsening or fibrosis improvement without worsening MASH.

Next Steps

Altimmune plans to begin the global PERFORMA Phase 3 trial in the second half of 2026. Pemvidutide has received both Fast Track and Breakthrough Therapy designations from the FDA for MASH.

Reference

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 – Altimmune

Study Details | NCT05989711 | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects with Nonalcoholic Steatohepatitis (NASH) | ClinicalTrials.gov

Advertisement · Remove ads
728 × 90
Reviewed by the Pharmacally Editorial Team
Every story is checked against primary sources.
Our editorial process →